The anti‐C5a antibody vilobelimab efficiently inhibits C5a in patients with severe COVID‐19-Reference-Cited by-同舟云学术

The anti‐C5a antibody vilobelimab efficiently inhibits C5a in patients with severe COVID‐19

Published:2022-01-14 Issue:4 Volume:15 Page:854-858
ISSN:1752-8054
Container-title:Clinical and Translational Science
language:en
Short-container-title:Clinical Translational Sci

Author:

Vlaar Alexander P. J.¹^ORCID,Lim Endry H. T.¹²^ORCID,Bruin Sanne¹^ORCID,Rückinger Simon³,Pilz Korinna⁴,Brouwer Matthijs C.²^ORCID,Guo Ren‐Feng⁵,Heunks Leo M. A.⁶^ORCID,Busch Matthias H.⁷^ORCID,Paassen Pieter⁷^ORCID,Riedemann Niels C.⁴^ORCID,Beek Diederik²^ORCID

Affiliation:

1. Department of Intensive Care University of Amsterdam Amsterdam UMC Amsterdam The Netherlands

2. Department of Neurology University of Amsterdam Amsterdam UMC Amsterdam Neuroscience Amsterdam The Netherlands

3. Metronomia Clinical Research GmbH Munich Germany

4. InflaRx GmbH Jena Germany

5. InflaRx Pharmaceuticals Inc. Ann Arbor Michigan USA

6. Department of Intensive Care VU Amsterdam Amsterdam UMC Amsterdam The Netherlands

7. Department of Immunology Maastricht UMC+ Maastricht The Netherlands

Publisher

Wiley

Subject

General Pharmacology, Toxicology and Pharmaceutics,General Biochemistry, Genetics and Molecular Biology,General Medicine,General Neuroscience

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cts.13213

Reference7 articles.

1. Association of COVID-19 inflammation with activation of the C5a–C5aR1 axis

2. Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial

3. Controlling the anaphylatoxin C5a in diseases requires a specifically targeted inhibition

4. Complement Inhibition in Severe COVID-19 Acute Respiratory Distress Syndrome

5. Eculizumab as an emergency treatment for adult patients with severe COVID-19 in the intensive care unit: A proof-of-concept study

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Review of COVID-19 Therapeutics by Mechanism: From Discovery to Approval;Journal of Korean Medical Science;2024

2. Targeting C5a is beneficial in critically ill COVID-19 patients;Immunobiology;2023-11

3. C5a-C5aR1 Axis Blockade in Patients With Severe COVID-19: Differences Between PANAMO and FORCE Study;Critical Care Medicine;2023-10-12

4. Inhibiting C5 in patients with severe COVID-19—the incorrect target?;The Lancet Respiratory Medicine;2023-09

5. The role of C5a receptors in autoimmunity;Immunobiology;2023-09